Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel study

References

• Ellis JA, Vroom E, Muntoni F. 195th ENMC international workshop: newborn screening for Duchenne muscular dystrophy 14-16th December, 2012, Naarden, The Netherlands. Neuromuscul Disord. 2013;23(8):808–689.
   Web of Science ®Google Scholar
• Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.
   PubMed Web of Science ®Google Scholar
• Emery AE. The muscular dystrophies. Lancet. 2002;359(9307):687–695.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Thompson R, Sejersen T, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(7):643–653.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Lindgren P, Bell CF, et al. Health-related quality of life in patients with Duchenne muscular dystrophy: a multi-national, cross-sectional study. Dev Med Child Neurol. 2016;58(5):508–515.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Edström J, Buccella F, et al. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018;60(10):987–996.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Lindgren P, Bell CF, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529–536.
   PubMed Web of Science ®Google Scholar
• Mackenzie SJ, Nicolau S, Connolly AM, et al. Therapeutic approaches for Duchenne muscular dystrophy: old and new. Semin Pediatr Neurol. 2021;37:100877.
   PubMed Web of Science ®Google Scholar
• Gammie T, Lu CY, Babar ZU. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLOS One. 2015;10(10):e0140002.
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Value Health. 2012;15(6):843–850.
   PubMed Web of Science ®Google Scholar
• Pichavant C, Aartsma-Rus A, Clemens PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther. 2011;19(5):830–840.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE guidance for ataluren. [cited 2018 May 1]. Available from: https://www.nice.org.uk/guidance.
   Google Scholar
• Project HERCULES. [cited 2021 Dec 11]. Available from: https://hercules.duchenneuk.org.
   Google Scholar
• Linstone H, Turoff M. The Delphi method: techniques and applications. Reading, MA. Addison-Wesley; 1975.
   Google Scholar
• Hsu CC, Sanford BA. The Delphi technique: making sense of consensus. Pract Assess Res Evaluation. 2007;12(10):1–8.
   Google Scholar
• Horsman J, Furlong W, Feeny D, et al. The health utilities index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.
   PubMedGoogle Scholar
• Landfeldt E, Lindberg C, Sejersen T. Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy. Muscle Nerve. 2020;61(3):363–368.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLOS One. 2013;8(12):e81302.
   PubMed Web of Science ®Google Scholar
• Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477–487.
   PubMed Web of Science ®Google Scholar
• McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–1498.
   PubMed Web of Science ®Google Scholar
• McDonald CM, Muntoni F, Penematsa V, et al. Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. J Comp Eff Res. 2022;11(3):139-155.
   Web of Science ®Google Scholar
• Mercuri E, Muntoni F, Buccella F, et al. Age at loss of ambulation in patients with DMD from the STRIDE registry and the CINRG Natural history study: a matched cohort analysis. Neuromuscular Disorders. 2021;31(Supplement 1):S92-S92.
   Google Scholar
• Powell C. The Delphi technique: myths and realities. J Adv Nurs. 2003;41(4):376–382.
   PubMed Web of Science ®Google Scholar
• McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451–461.
   PubMed Web of Science ®Google Scholar
• Trucco F, Domingos JP, Tay CG, et al. Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne muscular dystrophy: a single-site retrospective longitudinal study. Chest. 2020;158(4):1606–1616.
   PubMed Web of Science ®Google Scholar
• Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess. 2001;5(4):1–157.
   PubMedGoogle Scholar
• Williams K, Davidson I, Rance M, et al. Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model. J Patient Rep Outcomes. 2021;5(1):75.
   PubMedGoogle Scholar
• Donnelly CM, Quinlivan RM, Herron A, et al. A systematic review and qualitative synthesis of the experiences of parents of individuals living with Duchenne muscular dystrophy. Disabil Rehabil. 2022;1–14. DOI:10.1080/09638288.2022.2060336
   PubMedGoogle Scholar
• McMillan HJ, Gerber B, Cowling T, et al. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553–568.
   PubMedGoogle Scholar
• Ramos GF, Kuiper S, Dompeling E, et al. Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children. BMC Med Res Methodol. 2011;11:150.
   PubMed Web of Science ®Google Scholar